Russell Investments Group’s Axsome Therapeutics AXSM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$6.04M Buy
35,718
+143
+0.4% +$24.7K 0.01% 1245
2025
Q4
$6.5M Buy
35,575
+9,973
+39% +$1.39M 0.01% 1156
2025
Q3
$3.11M Buy
25,602
+7,798
+44% +$878K ﹤0.01% 1611
2025
Q2
$1.86M Buy
17,804
+15,166
+575% +$1.61M ﹤0.01% 1755
2025
Q1
$308K Sell
2,638
-16,799
-86% -$1.91M ﹤0.01% 2470
2024
Q4
$1.64M Buy
19,437
+18,422
+1,815% +$1.69M ﹤0.01% 1765
2024
Q3
$91.2K Sell
1,015
-819
-45% -$71.5K ﹤0.01% 2676
2024
Q2
$148K Buy
1,834
+1,043
+132% +$77.2K ﹤0.01% 2546
2024
Q1
$63.1K Buy
791
+777
+5,550% +$65.2K ﹤0.01% 2635
2023
Q4
$1.11K Sell
14
-8,950
-100% -$598K ﹤0.01% 3053
2023
Q3
$626K Sell
8,964
-15,635
-64% -$1.17M ﹤0.01% 2147
2023
Q2
$1.77M Buy
24,599
+24,578
+117,038% +$1.81M ﹤0.01% 1633
2023
Q1
$1.29K Buy
+21
New +$1.38K ﹤0.01% 3038
2021
Q4
Sell
-12,506
Closed -$411K 2996
2021
Q3
$411K Sell
12,506
-2,415
-16% -$94.1K ﹤0.01% 2546
2021
Q2
$1.01M Buy
14,921
+8,045
+117% +$483K ﹤0.01% 2311
2021
Q1
$388K Buy
6,876
+726
+12% +$51.1K ﹤0.01% 2620
2020
Q4
$500K Sell
6,150
-2,049
-25% -$153K ﹤0.01% 2427
2020
Q3
$583K Sell
8,199
-15,005
-65% -$1.17M ﹤0.01% 2321
2020
Q2
$1.9M Buy
23,204
+21,415
+1,197% +$1.65M ﹤0.01% 1674
2020
Q1
$105K Buy
+1,789
New +$146K ﹤0.01% 2718

Other funds holding AXSM

Russell Investments Group's AXSM Position: Q1 2026 in Review

Russell Investments Group increased its Axsome Therapeutics (AXSM) stake by 0.4% in Q1 2026, buying an estimated $24.7K and bringing the position to 35,718 shares worth $6.04M. The position accounts for 0.01% of the portfolio, ranked #1245.

Russell Investments Group first reported a position in AXSM in Q1 2020 and has held it in 20 quarters since. The position peaked at $6.5M in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Russell Investments Group held 35,718 shares of Axsome Therapeutics worth $6.04M as of Q1 2026.
  • Russell Investments Group bought 143 Axsome Therapeutics shares in Q1 2026, an estimated $24.7K.
  • Axsome Therapeutics made up 0.01% of Russell Investments Group's portfolio in Q1 2026, its #1245 holding.
  • Russell Investments Group first reported a position in Axsome Therapeutics in Q1 2020 and has held it in 20 quarters since.
  • Russell Investments Group's Axsome Therapeutics position peaked at $6.5M in Q4 2025.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Russell Investments Group's 13F filing for Q1 2026, filed 8 May 2026.